RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Targeted therapy shows promise for leukemia patients with hidden cancer cells
Disease control OngoingThis study tests a drug called inotuzumab ozogamicin in 40 adults with B-cell acute lymphoblastic leukemia who have minimal residual disease (small amounts of cancer left after treatment). The drug attaches to a marker on cancer cells and delivers a toxin to kill them. The goal i…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 06:10 UTC
-
New combo therapy shows promise for Tough-to-Treat leukemia
Disease control OngoingThis early-stage study tests a combination of three immunotherapy drugs (blinatumomab, nivolumab, and ipilimumab) in adults with a type of leukemia that has returned or not responded to standard treatment. The main goals are to find the safest dose and identify side effects. Abou…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:09 UTC
-
Immune therapy shows promise in battling relapsed childhood leukemia
Disease control OngoingThis study tests whether blinatumomab, a drug that helps the immune system attack leukemia cells, works better than standard chemotherapy for children and young adults (ages 1 to 30) whose B-cell acute lymphoblastic leukemia has returned after initial treatment. About 669 partici…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:07 UTC
-
New combo targets hard-to-treat leukemia in early trial
Disease control OngoingThis study tests a new drug combination (venetoclax plus vincristine) in 40 adults with T-cell or B-cell acute lymphoblastic leukemia that has returned or not responded to prior therapy. The goal is to find the safest dose and see if the combination helps achieve remission. Parti…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 26, 2026 06:00 UTC
-
New drug cocktail shows promise against rare leukemia
Disease control OngoingThis early-stage trial tests a combination of the oral drug venetoclax with standard chemotherapy and targeted therapies in adults with a specific, hard-to-treat leukemia (Ph+ ALL) that is either newly diagnosed or has returned. The main goal is to find the safest dose and see ho…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 26, 2026 05:50 UTC